 |
|
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online 2022 Dec 12 DOI: https://doi.org/10.3350/cmh.2022.0436
|
|
Citations to this article as recorded by
 The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
Journal of Gastroenterology and Hepatology.2024; 39(1): 193. CrossRef Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis
Tamer A. Addissouky, Majeed M. A. Ali, Ibrahim El Tantawy El Sayed, Yuliang Wang
The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
Jaejun Lee, Seungmyeon Choi, Seong-Hyun Cho, Hyun Yang, Pil-Soo Sung, Si-Hyun Bae
Diagnostics.2024; 14(4): 393. CrossRef TyG-GGT is a Reliable Non-Invasive Predictor of Advanced Liver Fibrosis in Overweight or Obese Individuals
Lei Jin, Jing Gu, Zhe Zhang, Cheng-Fei Du, Fei-Qi Xu, Xiao-Kun Huang, Zhen-Yu Gao, Ying Li, Li-Li Yu, Xin Zhang, Guo-Qing Ru, Jun-Wei Liu, Lei Liang, Xiao-Dong Sun, Zun-Qiang Xiao
Obesity Surgery.2024; 34(4): 1333. CrossRef Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283. CrossRef Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Liver Cancer.2024; : 1. CrossRef Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef Comparison between Two-Dimensional and Point Shear Wave Elastography Techniques in Evaluating Liver Fibrosis Using Histological Staging as the Reference Standard: A Prospective Pilot Study
Sang Lee, Hong Ha, In Lee, Kwanseop Lee, Jung Lee, Ji Park, Sung-Eun Kim, Mi Kwon, Ji-Young Choe, Sam-Youl Yoon, Seung-Gu Yeo, Min-Jeong Kim
Diagnostics.2023; 13(9): 1646. CrossRef The application of a novel platform of multiparametric magnetic resonance imaging in a bioenvironmental toxic carbon tetrachloride-induced mouse model of liver fibrosis
Liao Qiuling, Yu Qilin, Yu Cheng, Zhang Minping, Wang Kangning, Xiao Enhua
Environmental Research.2023; 238: 117130. CrossRef Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim
Cell Communication and Signaling.2023;[Epub] CrossRef Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis
Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li
Biomedical Reports.2023;[Epub] CrossRef
|